Skip to main content

Free Content Numbers of IFN-γ-producing cells against ESAT-6 increase in tuberculosis patients during chemotherapy [Technical Note]

Download Article:
(PDF 123.9 kb)


ESAT-6 is a specific Mycobacterium tuberculosis complex antigen and strong inducer of interferon-gamma (IFN-γ) production by T cells from tuberculosis patient T-cells. We studied the frequency of IFN-γ producing cells reacting to ESAT-6 during anti-tuberculosis chemotherapy. The numbers of IFN-γ producing cells in the peripheral blood were higher in tuberculosis patients after discharge from specific anti-tuberculosis chemotherapy, compared with untreated patients. These results indicate that monitoring specific M. tuberculosis antigen reactivity during anti-tuberculosis chemotherapy may avoid premature termination of treatment and resistant strains.

Keywords: ESAT-6 antigen; M. tuberculosis infection; human IFN-γ; human T-cells; tuberculosis

Document Type: Short Communication

Affiliations: Max-Planck Institute for Infection Biology, Department of Immunology, Berlin, Germany

Publication date: December 1, 2000

More about this publication?
  • The International Journal of Tuberculosis and Lung Disease publishes articles on all aspects of lung health, including public health-related issues such as training programmes, cost-benefit analysis, legislation, epidemiology, intervention studies and health systems research. The IJTLD is dedicated to the continuing education of physicians and health personnel and the dissemination of information on tuberculosis and lung health world-wide.

    Certain IJTLD articles are selected for translation into French, Spanish, Chinese or Russian. They are available on the Union website

  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • International Journal of Tuberculosis and Lung Disease
  • Public Health Action
  • Ingenta Connect is not responsible for the content or availability of external websites

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more